Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05460273 · FLOW

Participant flow

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Final Analysis with DCO on 27Nov2024
    id
    FG000
    title
    Dato-DXd_NSCLC
  2. description
    Final Analysis with DCO on 06May2024
    id
    FG001
    title
    Dato-DXd_TNBC
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        27
      2. group Id
        FG001
        num Subjects
        43
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        7
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        40
      2. group Id
        FG001
        num Subjects
        79
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        13
      2. group Id
        FG001
        num Subjects
        29
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        27
      2. group Id
        FG001
        num Subjects
        50
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Overall 168 participants were screened at 23 centers in China. A total of 119 participants were treated with Dato-DXd. For TNBC cohort, 106 participant was screened at 14 centers in China. 79 participants received Dato-DXd at the 14 centers. For NSCLC cohort, 62 participant was screened at 12 centers in China. 40 participants received Dato-DXd at 11 centers. Note: 3 centers screened both TNBC participants and NSCLC participants.
recruitment Details
This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China. For TNBC cohort, first participant was screened on 11Jul2022, last participant was screened on 27Apr2023. For NSCLC cohort, first participant was screened on 29Aug2022, last participant was screened on 21Mar2023.
Complete source fields
groups
  1. description
    Final Analysis with DCO on 27Nov2024
    id
    FG000
    title
    Dato-DXd_NSCLC
  2. description
    Final Analysis with DCO on 06May2024
    id
    FG001
    title
    Dato-DXd_TNBC
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        27
      2. group Id
        FG001
        num Subjects
        43
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        7
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        40
      2. group Id
        FG001
        num Subjects
        79
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        13
      2. group Id
        FG001
        num Subjects
        29
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        27
      2. group Id
        FG001
        num Subjects
        50
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Overall 168 participants were screened at 23 centers in China. A total of 119 participants were treated with Dato-DXd. For TNBC cohort, 106 participant was screened at 14 centers in China. 79 participants received Dato-DXd at the 14 centers. For NSCLC cohort, 62 participant was screened at 12 centers in China. 40 participants received Dato-DXd at 11 centers. Note: 3 centers screened both TNBC participants and NSCLC participants.
recruitment Details
This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China. For TNBC cohort, first participant was screened on 11Jul2022, last participant was screened on 27Apr2023. For NSCLC cohort, first participant was screened on 29Aug2022, last participant was screened on 21Mar2023.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice